Heart transplantation in patients with severe pulmonary hypertension and increased pulmonary vascular resistance.
Irreversibly increased pulmonary vascular resistance is a contraindication for cardiac transplantation. At our hospital patients referred for recipient evaluation with systolic pulmonary artery pressure greater than 50 mmHg and pulmonary vascular resistance greater than 2 Wood units (Wu) are tested with intravenous sodium nitroprusside for reversibility. In 23 patients whose increased systolic pulmonary artery pressure (67.4 +/- 10.4 mmHg) and resistance (4.8 +/- 2.4 Wu) were reduced by nitroprusside, orthotopic heart transplantation was performed without early mortality. Right heart catheterization after transplantation revealed a significant and persistent fall of the elevated pulmonary artery pressure and pulmonary vascular resistance. We conclude that if severe pulmonary hypertension and elevated pulmonary vascular resistance are reversible with nitroprusside, the patient can safely undergo heart transplantation.
Simonsen
S
S
Medical Department B, Rikshospitalet, Oslo, Norway.
Mølstad
P
P
Geiran
O
O
Frøysaker
T
T
D000328:Adult; D006328:Cardiac Catheterization; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000503:physiopathology / Q000601:surgery; D000075202:Contraindications; D003327:Coronary Disease / Q000150:complications / Q000503:physiopathology / Q000601:surgery; D005260:Female; D016027:Heart Transplantation; D006349:Heart Valve Diseases / Q000150:complications / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000503:physiopathology / Q000601:surgery; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009599:Nitroprusside; D011184:Postoperative Period; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D009599:Nitroprusside